UCB ：製藥企業分析報告 是由出版商Espicom Business Intelligence在2010年01月所出版的。
這份英文市場調查報告書包含Pages: 82 價格從美金1040起跳。
Abstract
UCB is a global biopharmaceutical company dedicated to the research,
development and commercialisation of innovative pharmaceutical and
biotechnology products in the fields of CNS disorders, allergy/respiratory
diseases, immune and inflammatory disorders, plus oncology. Headquartered in
Brussels, Belgium, it has over 12,000 employees worldwide.
The Group has production and packaging facilities in Belgium, Switzerland, the
US, Japan, Germany, India, Italy, Spain and South Korea and sells in more than
40 countries on all continents. During 2005, the Group disposed of the Surface
Specialties business segment and transformed itself into a pure
biopharmaceutical company. The recent acquisitions of Celltech and Schwarz
Pharma should help establish UCB as one the leading biopharmaceutical
companies in Europe.
The divestiture of the Surface Specialities segment in 2005 has negatively
impacted total company revenue insubsequent fiscal years despite strong growth
in the Pharmaceutical segment, which was boosted by the acquisition of
Celltech in 2004. The purchase of Schwarz Pharma, which was completed in July
2007, helped return company revenue in fiscal 2007 to positive growth for the
first time since 2004. However, in fiscal 2008, revenue declined once more,
this time due to the loss of market exclusivity for the key products Keppra
and, in particular, Zyrtec.
UCB' s current top-selling product is Keppra, a leading epilepsy therapy, which
has recorded peak sales of over EUR 1 billion. The loss of patent protection
is expected to heavily impact sales and prior to the acquisition of Schwarz,
it appeared UCB would not have the resources to offset these losses. However,
UCB now sells Schwarz-developed Neupro, a novel Parkinson' s disease treatment
recently approved in the US and Europe. Sales of Neupro are forecast to reach
EUR 166 million in 2013, and combined with launches and sales for promising
late-stage pipeline products such as Cimzia and Vimpat, the impact of falling
sales of Keppra is expected to be considerably dampened.
Nonetheless, long-term growth remains threatened by this patent loss and UCB
will have to make significant investment in R&D and seek to in-licence new
products to further expand the product portfolio. The acquisition of Schwarz
brings with it substantial expertise and research infrastructure in the field
of biotechnology and in particular the treatment of CNS disorders.
Consequently, UCB now has the tools required to overcome the difficulties
anticipated with Keppra and to further re-enforce its position as one of the
leading biopharmaceutical companies in Europe.
This new strategic analysis report UCB: Pipeline - Products - Performance -
Potential, provides a complete and critical review of the company and
includes unique and independent assessments and forecasts of key products.
Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Acquisitions
- Divestitures
- Key Agreements
- Production
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D projects
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Keppra
- Metadate CD/Equasym XL
- Neupro
- Vimpat
- Others
- R&D Projects
- Growth Forecast
- IMMUNO-ALLERGOLOGY
- Marketed Products
- Cimzia
- Xyzal/Xusal
- Zyrtec/Reactine
- Others
- R&D Projects
- Growth Forecast
- OTHERS
- Marketed Products
- R&D Projects
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Actelion Ltd.
- Alembic Limited
- Amgen
- AstraZeneca
- Azur Pharma Inc.
- Biogen Idec Inc.
- BioInvent International AB
- BioWa Inc.
- Immunomedics Inc.
- Lonza Biologics Ltd.
- Merck & Co
- Nektar Therapeutics
- Novartis
- Orphan Medical Inc.
- Otsuka
- Pfizer
- sanofi-aventis
- Sepracor Inc
- Teva Pharmaceutical Industries Inc.
- Verus Pharmaceuticals Inc.
- Wilex AG
- APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Royalty Income
- Net Pharmaceutical Sales By Geographical Area
- Net Sales By Geographical Area, 2008
- Recent Product Approvals
- Sales Of Major Biopharmaceutical Products
- Major CNS Products, 2008
- Major Immuno-allergology Products, 2008
- Major Other Products, 2008
INDEX OF CHARTS
- Royalty Income, 2008
- Sales of Top Ten Products (2003A-2013E)
- Top Selling Products, 2008
- Keppra Sales (2003A-2013E)
- Metadate Sales (2004A-2013E)
- Neupro Sales (2006A-2013E)
- Vimpat Sales (2009E-2013E)
- Bivaracetam Sales (2010E-2014E)
- Cimzia Sales (2008A-2013E)
- Xyzal Sales (2004A-2013E)
- Zyrtec Sales (2003A-2013E)
- Epratuzumab Sales (2010E-2014E)
- Tussionex Sales (2004A-2013E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
